Compare GSK plc (GSK) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs QUALCOMM, Inc. — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while QUALCOMM, Inc. trades at $170.61 (market cap $187.59B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | QCOM | |
|---|---|---|
Market Cap | $101.34B | $187.59B |
Sector | Health | Technology |
52-Week High | $61.18 | $251.10 |
52-Week Low | $36.20 | $124.07 |
Enterprise Value | $121.95B | $193.06B |
Dividend Yield | 3.49% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Qualcomm (QCOM) trades at $178.08, down 3.21% today, amid a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.65 surpassing the $2.56 forecast. The company maintains strong profitability with a 54.8% gross margin and 22.31% net income margin, while diversifying into AI and automotive markets. News highlights Nvidia's entry into the PC chip market increasing competitive pressures.
The outlook is cautiously optimistic with a consensus price target of $222.53 implying 25% upside, but near-term risks include smartphone demand softness and margin pressures. Long-term growth hinges on successful expansion in AI and data centers, though competition and market volatility pose challenges to shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
